FATE Latest News, Press Relases and Analysis

All

Press Releases

21 hours ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

21 hours ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

14 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

14 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

7 months ago - By: Benzinga

4 Analysts Assess Fate Therapeutics: What You Need To Know

26 days ago - By: Zacks Investment Research - Mentions: BTCY

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

26 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

26 days ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Zacks Investment Research - Mentions: ARCT

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

a month ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Benzinga - Mentions: NBY APDN GOVX SCYX ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Upcoming Investor Conferences

4 months ago - By: Zacks Investment Research - Mentions: RNA

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

4 months ago - By: Zacks Investment Research - Mentions: ENTA

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: HCAT

Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates

4 months ago - By: Zacks Investment Research - Mentions: VRDN

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Fate Therapeutics, Inc.